About AURA

Comprehensive, coordinated and effective surveillance of antimicrobial resistance and antimicrobial use is a national priority and a critical component of the Australia’s First National Antimicrobial Resistance Strategy 2015–2019.  The Commission has developed the AURA Surveillance System to support strategies to prevent and contain AMR.

AURA coordinates data from a range of sources to provide a comprehensive and integrated picture of patterns and trends of AMR and antimicrobial use across Australia.  Four core long-term surveillance programs provide the foundation for the AURA Surveillance System:

  • Australian Group on Antimicrobial Resistance
  • National Antimicrobial Prescribing Survey
  • National Antimicrobial Utilisation Surveillance Program
  • Queensland Health OrgTRx System, which provides the infrastructure for the National Passive AMR Surveillance System.

In addition, data and reports are gathered from:

  • The National Neisseria Network, on Neisseria gonorrhoeae and meningitidis
  • The National Notifiable Diseases Surveillance System, on Mycobacterium tuberculosis
  • The Pharmaceutical Benefits Scheme (PBS) and Repatriation Pharmaceutical Benefits Scheme (RPBS)
  • The NPS MedicineWise MedicineInsight program
  • Sullivan Nicolaides Pathology, on rates of AMR from the community and private hospital settings.

During 2016, the Commission also established the National Alert System for Critical Antimicrobial Resistances (CARAlert) which collects surveillance data on priority organisms that are resistant to last-line antimicrobials.